Structural simplification: an efficient strategy in lead optimization
暂无分享,去创建一个
[1] L. Weber. The application of multi-component reactions in drug discovery. , 2002, Current medicinal chemistry.
[2] P. Paira,et al. Discovery of simplified N²-substituted pyrazolo[3,4-d]pyrimidine derivatives as novel adenosine receptor antagonists: efficient synthetic approaches, biological evaluations and molecular docking studies. , 2014, Bioorganic & medicinal chemistry.
[3] H. Hussain,et al. Lapachol: An overview , 2007 .
[4] G. T. Liu. Therapeutic effects of biphenyl dimethyl dicarboxylate (DDB) on chronic viral hepatitis B. , 1987, Proceedings of the Chinese Academy of Medical Sciences and the Peking Union Medical College = Chung-kuo i hsueh k'o hsueh yuan, Chung-kuo hsieh ho i k'o ta hsueh hsueh pao.
[5] György M Keseru,et al. Hit discovery and hit-to-lead approaches. , 2006, Drug discovery today.
[6] R. Bosotti,et al. Cdc7 kinase inhibitors: pyrrolopyridinones as potential antitumor agents. 1. Synthesis and structure-activity relationships. , 2008, Journal of medicinal chemistry.
[7] S. Tepper,et al. Clinical and Preclinical Rationale for CGRP‐Receptor Antagonists in the Treatment of Migraine , 2008, Headache.
[8] M. Faul,et al. (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta. , 1996, Journal of medicinal chemistry.
[9] J. Glorioso,et al. Protocol Optimization for the Production of the Non-Cytotoxic JΔNI5 HSV Vector Deficient in Expression of Immediately Early Genes , 2020, Molecular therapy. Methods & clinical development.
[10] C. Ghelardini,et al. Molecular simplification of 1,4-diazabicyclo[4.3.0]nonan-9-ones gives piperazine derivatives that maintain high nootropic activity. , 2000, Journal of medicinal chemistry.
[11] James D White,et al. Morphine, the Proteus of organic molecules. , 2002, Chemical communications.
[12] Herbert Waldmann,et al. Highly enantioselective synthesis and cellular evaluation of spirooxindoles inspired by natural products , 2010, Nature Chemistry.
[13] M. Faul,et al. Acyclic N-(azacycloalkyl)bisindolylmaleimides: isozyme selective inhibitors of PKCbeta. , 2003, Bioorganic & medicinal chemistry letters.
[14] S. Matthews,et al. Crystal structure of human CDC7 kinase in complex with its activator DBF4 , 2012, Nature Structural &Molecular Biology.
[15] Alejandra Prieto-Davó,et al. Antibiotic terpenoid chloro-dihydroquinones from a new marine actinomycete. , 2005, Journal of natural products.
[16] Shengzheng Wang,et al. Structural Simplification of Natural Products. , 2019, Chemical reviews.
[17] A. W. Shaw,et al. Potent, orally bioavailable calcitonin gene-related peptide receptor antagonists for the treatment of migraine: discovery of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1- (2,2,2-trifluoroethyl)azepan-3-yl]-4- (2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin- 1-yl)piperidine-1-carboxamide (MK-0974). , 2007, Journal of medicinal chemistry.
[18] Stefan Wetzel,et al. Interactive exploration of chemical space with Scaffold Hunter. , 2009, Nature chemical biology.
[19] J. Fudin,et al. Levorphanol use: past, present and future , 2016, Postgraduate medicine.
[20] Yaxue Zhao,et al. Discovery of N-(4-sulfamoylphenyl)thioureas as Trypanosoma brucei leucyl-tRNA synthetase inhibitors. , 2013, Organic & biomolecular chemistry.
[21] Richard Pazdur,et al. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. , 2007, The oncologist.
[22] J. Ovádi,et al. New anti-mitotic drugs with distinct anti-calmodulin activity. , 2006, Mini reviews in medicinal chemistry.
[23] G. Schneider,et al. Counting on Natural Products for Drug Design , 2016 .
[24] Petra Schneider,et al. Multi-objective molecular de novo design by adaptive fragment prioritization. , 2014, Angewandte Chemie.
[25] S. Moro,et al. 4-amido-2-aryl-1,2,4-triazolo[4,3-a]quinoxalin-1-ones as new potent and selective human A3 adenosine receptor antagonists. synthesis, pharmacological evaluation, and ligand-receptor modeling studies. , 2006, Journal of medicinal chemistry.
[26] T. Fujita,et al. Simple compounds, 2-alkyl-2-amino-1,3-propanediols have potent immunosuppressive activity , 1995 .
[27] T. Fujita,et al. 2-Substituted 2-aminoethanol: Minimum essential structure for immunosuppressive activity of ISP-I (Myriocin) , 1995 .
[28] R. Reiter,et al. Cardioprotective Role of Melatonin in Acute Myocardial Infarction , 2020, Frontiers in Physiology.
[29] S. Rogelj,et al. Structural simplification of bioactive natural products with multicomponent synthesis. 2. antiproliferative and antitubulin activities of pyrano[3,2-c]pyridones and pyrano[3,2-c]quinolones. , 2008, Journal of medicinal chemistry.
[30] D. Uemura,et al. Halichondrins - antitumor polyether macrolides from a marine sponge , 1986 .
[31] A. Waterson,et al. Development of potent B-RafV600E inhibitors containing an arylsulfonamide headgroup. , 2011, Bioorganic & medicinal chemistry letters.
[32] J. Tanaka,et al. Norhalichondrin A: an antitumor polyether macrolide from a marine sponge , 1985 .
[33] J. Stowell,et al. The synthesis of N-hydroxy-N'-phenyloctanediamide and its inhibitory effect on proliferation of AXC rat prostate cancer cells. , 1995, Journal of medicinal chemistry.
[34] W Patrick Walters,et al. What do medicinal chemists actually make? A 50-year retrospective. , 2011, Journal of medicinal chemistry.
[35] A. Saxena,et al. Novel, potent, orally bioavailable and selective mycobacterial ATP synthase inhibitors that demonstrated activity against both replicating and non-replicating M. tuberculosis. , 2015, Bioorganic & medicinal chemistry.
[36] I. Chopra,et al. Prospects for Aminoacyl-tRNA Synthetase Inhibitors as New Antimicrobial Agents , 2005, Antimicrobial Agents and Chemotherapy.
[37] J. Vederas,et al. Natural products and their derivatives as tRNA synthetase inhibitors and antimicrobial agents , 2016 .
[38] C. Niemegeers,et al. Synthetic analgesics. Synthesis and pharmacology of the diastereoisomers of N-(3-methyl-1-(2-phenylethyl)-4-piperidyl)-N-phenylpropanamide and N-(3-methyl-1-(1-methyl-2-phenylethyl)-4-piperidyl)-N-phenylpropanamide. , 1974, Journal of medicinal chemistry.
[39] M. Hann,et al. Finding the sweet spot: the role of nature and nurture in medicinal chemistry , 2012, Nature Reviews Drug Discovery.
[40] Tiffany L. Kinnibrugh,et al. Anticancer properties of an important drug lead podophyllotoxin can be efficiently mimicked by diverse heterocyclic scaffolds accessible via one-step synthesis. , 2011, Journal of medicinal chemistry.
[41] D. Hoyer,et al. SRA880, in vitro characterization of the first non-peptide somatostatin sst1 receptor antagonist , 2004, Neuroscience Letters.
[42] Guoqiang Dong,et al. Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections. , 2018, Journal of medicinal chemistry.
[43] M. Millan. N-Methyl-d-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives , 2005, Psychopharmacology.
[44] Stefan Wetzel,et al. Biology-oriented synthesis. , 2011, Angewandte Chemie.
[45] W. Leonard,et al. Mutation of Jak3 in a Patient with SCID: Essential Role of Jak3 in Lymphoid Development , 1995, Science.
[46] David W Dodick,et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial , 2008, The Lancet.
[47] Andrew T Maynard,et al. Quantifying, Visualizing, and Monitoring Lead Optimization. , 2016, Journal of medicinal chemistry.
[48] Kam Y. J. Zhang,et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity , 2008, Proceedings of the National Academy of Sciences.
[49] Stefan Wetzel,et al. Bioactivity-guided mapping and navigation of chemical space. , 2009, Nature chemical biology.
[50] A. Hyman,et al. Natural product-inspired cascade synthesis yields modulators of centrosome integrity. , 2012, Nature chemical biology.
[51] J. McKerrow,et al. A Cysteine Protease Inhibitor Protects Dogs from Cardiac Damage during Infection by Trypanosoma cruzi , 2005, Antimicrobial Agents and Chemotherapy.
[52] Craig J. Forsyth,et al. Total synthesis of halichondrin B and norhalichondrin B , 1992 .
[53] J. Vacca,et al. Novel CGRP receptor antagonists through a design strategy of target simplification with addition of molecular flexibility. , 2009, Bioorganic & medicinal chemistry letters.
[54] Gisbert Schneider,et al. Scaffold diversity of natural products: inspiration for combinatorial library design. , 2008, Natural product reports.
[55] J M Liesch,et al. A potent nonpeptide cholecystokinin antagonist selective for peripheral tissues isolated from Aspergillus alliaceus. , 1985, Science.
[56] J. King,et al. The Synthesis of Some Fluorene Derivatives1 , 1955 .
[57] R. S. Ferreira,et al. Synthesis and biological evaluation of potential inhibitors of the cysteine proteases cruzain and rhodesain designed by molecular simplification. , 2017, Bioorganic & medicinal chemistry.
[58] K. Scheidt,et al. Pyrrolidinyl-spirooxindole natural products as inspirations for the development of potential therapeutic agents. , 2007, Angewandte Chemie.
[59] Herbert Waldmann,et al. Design of compound libraries based on natural product scaffolds and protein structure similarity clustering (PSSC). , 2005, Molecular bioSystems.
[60] Zhiyan Xiao,et al. Strategies for the Optimization of Natural Leads to Anticancer Drugs or Drug Candidates , 2016, Medicinal research reviews.
[61] Martha Donoghue,et al. Eribulin Mesylate for the Treatment of Patients with Refractory Metastatic Breast Cancer: Use of a “Physician's Choice” Control Arm in a Randomized Approval Trial , 2012, Clinical Cancer Research.
[62] Herbert Waldmann,et al. Biology-oriented synthesis: harnessing the power of evolution. , 2014, Journal of the American Chemical Society.
[63] Herbert Waldmann,et al. Biology-oriented synthesis of a natural-product inspired oxepane collection yields a small-molecule activator of the Wnt-pathway , 2011, Proceedings of the National Academy of Sciences.
[64] Herbert Waldmann,et al. Natural product inspired compound collections: evolutionary principle, chemical synthesis, phenotypic screening, and target identification. , 2017, Drug discovery today. Technologies.
[65] P. L. McCormack,et al. Trametinib: First Global Approval , 2013, Drugs.
[66] James Tsai,et al. RAF inhibitors that evade paradoxical MAPK pathway activation , 2015, Nature.
[67] Zongru Guo,et al. The modification of natural products for medical use , 2016, Acta pharmaceutica Sinica. B.
[68] Meir Glick,et al. Construction of a 3D-shaped, natural product like fragment library by fragmentation and diversification of natural products. , 2017, Bioorganic & medicinal chemistry.
[69] A. Montagnoli,et al. Cdc7 Inhibition Reveals a p53-Dependent Replication Checkpoint That Is Defective in Cancer Cells , 2004, Cancer Research.
[70] A. Ziering,et al. Piperidine derivatives; 1,3-dialkyl-4-aryl-4-acyloxypiperidines. , 1947, The Journal of organic chemistry.
[71] L. Fan,et al. Butorphanol: effects of a prototypical agonist-antagonist analgesic on kappa-opioid receptors. , 2005, Journal of pharmacological sciences.
[72] K D Paull,et al. Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data. , 1991, The Journal of biological chemistry.
[73] B. E. Evans,et al. Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. , 1988, Journal of Medicinal Chemistry.
[74] B. E. Evans,et al. Design of nonpeptidal ligands for a peptide receptor: cholecystokinin antagonists. , 1987, Journal of medicinal chemistry.
[75] Lynda Tremblay,et al. Macrocyclic ketone analogues of halichondrin B. , 2004, Bioorganic & medicinal chemistry letters.
[76] Alastair J. King,et al. Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors. , 2013, ACS medicinal chemistry letters.
[77] C. De Virgilio,et al. Leucyl-tRNA synthetase controls TORC1 via the EGO complex. , 2012, Molecular cell.
[78] J. Levine,et al. Synergism between the analgesic actions of morphine and pentazocine , 1988, Pain.
[79] N-Leucinyl Benzenesulfonamides as Structurally Simplified Leucyl-tRNA Synthetase Inhibitors. , 2018, ACS medicinal chemistry letters.
[80] M. Hilgers,et al. Identification of bacteria-selective threonyl-tRNA synthetase substrate inhibitors by structure-based design. , 2013, Journal of medicinal chemistry.
[81] J. Johnston,et al. Signaling by IL‐2 and related cytokines: JAKs, STATs, and relationship to immunodeficiency , 1996, Journal of leukocyte biology.
[82] Stefan Wetzel,et al. The Scaffold Tree - Visualization of the Scaffold Universe by Hierarchical Scaffold Classification , 2007, J. Chem. Inf. Model..
[83] Kai Gao,et al. Theory and applications of differential scanning fluorimetry in early-stage drug discovery , 2020, Biophysical Reviews.
[84] S. Moro,et al. The identification of the 2-phenylphthalazin-1(2H)-one scaffold as a new decorable core skeleton for the design of potent and selective human A3 adenosine receptor antagonists. , 2011, Journal of medicinal chemistry.
[85] A. Schuffenhauer,et al. Charting biologically relevant chemical space: a structural classification of natural products (SCONP). , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[86] B. E. Evans,et al. Design of potent, orally effective, nonpeptidal antagonists of the peptide hormone cholecystokinin. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[87] Thomas Böttcher,et al. An Additive Definition of Molecular Complexity , 2016, J. Chem. Inf. Model..
[88] José L Medina-Franco,et al. The many roles of molecular complexity in drug discovery. , 2017, Drug discovery today.
[89] J. Coyle,et al. Modulation of N-methyl-D-aspartate receptor function by glycine transport. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[90] C. Peyssonnaux,et al. The Raf/MEK/ERK pathway: new concepts of activation , 2001, Biology of the cell.
[91] N. Oku,et al. Antiproliferative naphthoquinone esters from Rhinacanthus nasutus Kurz. roots on various cancer cells , 2006 .
[92] Kyoung Tai No,et al. Natural products used as a chemical library for protein-protein interaction targeted drug discovery. , 2018, Journal of molecular graphics & modelling.
[93] S. Moro,et al. Scouting human A3 adenosine receptor antagonist binding mode using a molecular simplification approach: from triazoloquinoxaline to a pyrimidine skeleton as a key study. , 2007, Journal of medicinal chemistry.
[94] A. Van Aerschot,et al. Aminoacyl-tRNA synthetase inhibitors as potential antibiotics. , 2011, European journal of medicinal chemistry.
[95] H. Kosterlitz,et al. Selectivity of ligands for opioid receptors , 1993 .
[96] Herbert Waldmann,et al. Bioactivity-guided navigation of chemical space. , 2010, Accounts of chemical research.
[97] A. Isacchi,et al. First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery. , 2009, Journal of medicinal chemistry.
[98] K. Gademann,et al. Capturing Biological Activity in Natural Product Fragments by Chemical Synthesis , 2016, Angewandte Chemie.
[99] Jayaraman Chandrasekhar,et al. Strategies and tactics for optimizing the Hit-to-Lead process and beyond--a computational chemistry perspective. , 2008, Drug discovery today.
[100] M. Hann. Molecular obesity, potency and other addictions in drug discovery , 2011 .
[101] M. Hines,et al. Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection. , 2010, Journal of medicinal chemistry.
[102] S. Moro,et al. The significance of 2-furyl ring substitution with a 2-(para-substituted) aryl group in a new series of pyrazolo-triazolo-pyrimidines as potent and highly selective hA(3) adenosine receptors antagonists: new insights into structure-affinity relationship and receptor-antagonist recognition. , 2010, Journal of medicinal chemistry.
[103] J. O’Shea,et al. Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor , 2003, Science.
[104] Brian K. Shoichet,et al. Increasing Chemical Space Coverage by Combining Empirical and Computational Fragment Screens , 2014, ACS chemical biology.
[105] T. Okumoto,et al. Fungal metabolites. Part 14. Novel potent immunosuppressants, mycestericins, produced by Mycelia sterilia. , 1994, The Journal of antibiotics.
[106] S. Horinouchi,et al. Trichostatin A and trapoxin: Novel chemical probes for the role of histone acetylation in chromatin structure and function , 1995, BioEssays : news and reviews in molecular, cellular and developmental biology.
[107] Pascale Romby,et al. Structural basis of translational control by Escherichia coli threonyl tRNA synthetase , 2002, Nature Structural Biology.
[108] Jaroslaw Polanski,et al. The analysis of the market success of FDA approvals by probing top 100 bestselling drugs , 2016, Journal of Computer-Aided Molecular Design.
[109] Geng-tao Liu. Bicyclol: a novel drug for treating chronic viral hepatitis B and C. , 2009, Medicinal chemistry (Shariqah (United Arab Emirates)).
[110] C. Ghelardini,et al. Design, synthesis, and preliminary pharmacological evaluation of 1, 4-diazabicyclo[4.3.0]nonan-9-ones as a new class of highly potent nootropic agents. , 2000, Journal of medicinal chemistry.
[111] Stefan Wetzel,et al. Natural-product-derived fragments for fragment-based ligand discovery , 2012, Nature Chemistry.
[112] T. Steitz,et al. Insights into editing from an ile-tRNA synthetase structure with tRNAile and mupirocin. , 1999, Science.
[113] I. Shih,et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. , 2003, Journal of the National Cancer Institute.
[114] R. N. Brogden,et al. Butorphanol: A Review of its Pharmacological Properties and Therapeutic Efficacy , 1978, Drugs.
[115] F. Giles,et al. Cdc7 kinase - a new target for drug development. , 2010, European journal of cancer.
[116] J. Majoral,et al. Compound high-quality criteria: a new vision to guide the development of drugs, current situation. , 2016, Drug discovery today.
[117] A. Isacchi,et al. Cdc7 kinase inhibitors: 5-heteroaryl-3-carboxamido-2-aryl pyrroles as potential antitumor agents. 1. Lead finding. , 2010, Journal of medicinal chemistry.
[118] R. Mahajan. Bedaquiline: First FDA-approved tuberculosis drug in 40 years , 2013, International journal of applied & basic medical research.
[119] A. Phillips,et al. The halichondrins and E7389. , 2009, Chemical reviews.
[120] Andrew R. Leach,et al. Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery , 2001, J. Chem. Inf. Comput. Sci..
[121] S. Moro,et al. New 2-arylpyrazolo[3,4-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies. , 2007, Journal of medicinal chemistry.
[122] I. Magedov. Structural Simplification of Bioactive Natural Products with Multicomponent Synthesis. Part 4. 4H-Pyrano-[2,3-b]naphthoquinones with Anticancer Activity. , 2012 .
[123] E. Pinard,et al. Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1. , 2008, Bioorganic & medicinal chemistry letters.
[124] Melvin J. Yu,et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. , 2001, Cancer research.
[125] S. Moro,et al. 2-Phenylpyrazolo[4,3-d]pyrimidin-7-one as a new scaffold to obtain potent and selective human A3 adenosine receptor antagonists: new insights into the receptor-antagonist recognition. , 2009, Journal of medicinal chemistry.
[126] R. Turnaturi,et al. (+)-and (-)-Phenazocine enantiomers: Evaluation of their dual opioid agonist/σ1 antagonist properties and antinociceptive effects. , 2017, European journal of medicinal chemistry.
[127] Tudor I. Oprea,et al. Is There a Difference between Leads and Drugs? A Historical Perspective , 2001, J. Chem. Inf. Comput. Sci..
[128] L. Geng. The anti-virus and hepatoprotective effect of bicyclol and its mechanism of action , 2001 .
[129] S. Van slambrouck,et al. Structural simplification of bioactive natural products with multicomponent synthesis. 4. 4H-pyrano-[2,3-b]naphthoquinones with anticancer activity. , 2012, Bioorganic & medicinal chemistry letters.
[130] Stefan Wetzel,et al. Charting, navigating, and populating natural product chemical space for drug discovery. , 2012, Journal of medicinal chemistry.
[131] L. Eckhardt-Strelau,et al. Structure of the mycobacterial ATP synthase Fo rotor ring in complex with the anti-TB drug bedaquiline , 2015, Science Advances.
[132] Hui Wen,et al. Structural Simplification of Bedaquiline: the Discovery of 3‐(4‐(N,N‐Dimethylaminomethyl)phenyl)quinoline‐Derived Antitubercular Lead Compounds , 2016, ChemMedChem.
[133] Jeremy J. Yang,et al. Structural simplification of bioactive natural products with multicomponent synthesis. 3. Fused uracil-containing heterocycles as novel topoisomerase-targeting agents. , 2011, Journal of medicinal chemistry.
[134] D. Hoyer,et al. Discovery of novel non-peptidic beta-alanine piperazine amide derivatives and their optimization to achiral, easily accessible, potent and selective somatostatin sst1 receptor antagonists. , 2009, Bioorganic & medicinal chemistry letters.
[135] Won Kyung Kim,et al. Discovery of simplified leucyladenylate sulfamates as novel leucyl-tRNA synthetase (LRS)-targeted mammalian target of rapamycin complex 1 (mTORC1) inhibitors. , 2016, Bioorganic & medicinal chemistry.
[136] Michael J. Keiser,et al. Complementarity Between a Docking and a High-Throughput Screen in Discovering New Cruzain Inhibitors† , 2010, Journal of medicinal chemistry.
[137] Sunghoon Kim,et al. Leucyl-tRNA Synthetase Is an Intracellular Leucine Sensor for the mTORC1-Signaling Pathway , 2012, Cell.
[138] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.